Ankylosing SpondylitisNCT07907913
SLAMF1 Gene Expression in Ankylosing Spondylitis
An observational study of Ankylosing Spondylitis, run by Assiut University.
Trial summary
This cross-sectional study aims to evaluate SLAMF1 gene expression levels in patients with ankylosing spondylitis compared with healthy controls. Read more about this study
- Who is it for?
- Ages 18 years and olderHealthy volunteers can take part
- Conditions the study is for
- Ankylosing Spondylitis
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 30 Oct 2026to 25 Mar 2028
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Study population: Adult patients aged 18 years or older diagnosed with ankylosing spondylitis and age- and sex-matched healthy controls at Assiut University Hospitals.
Who may be able to join
- Adult Egyptian patients aged 18 years or older
- Diagnosed with ankylosing spondylitis according to established clinical criteria (patient group)
- Apparently healthy adults matched for age and sex (control group)
- Written informed consent
Who cannot join
- Other concomitant systemic autoimmune or inflammatory rheumatic diseases
- Active acute infection at blood sampling
- Current malignancy or active anticancer treatment
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Study of Signaling Lymphocytic Activation Molecule Family Member 1 (SLAMF1) Gene Expression in Patients With Ankylosing Spondylitis
This cross-sectional study aims to evaluate SLAMF1 gene expression levels in patients with ankylosing spondylitis compared with healthy controls.
Read the detailed description
Ankylosing spondylitis is a chronic immune-mediated inflammatory disease affecting the axial skeleton. SLAMF1 is a cell-surface immunoregulatory receptor expressed on immune cells that may play a role in inflammatory responses.
This observational study will measure relative SLAMF1 gene expression by real-time PCR in adult patients with ankylosing spondylitis and age- and sex-matched healthy controls.
- Conditions
- Ankylosing Spondylitis
- Keywords
- SLAMF1, Gene expression, Ankylosing spondylitis, BASDAI, Assiut
- Medical subject headings
- Spondylitis, Ankylosing
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with Ankylosing Spondylitis | Adult patients diagnosed with ankylosing spondylitis. | |
| Healthy Controls | Age- and sex-matched apparently healthy adults without inflammatory rheumatic disease. |
What is being measured
The primary outcome is the main question the study is designed to answer.
SLAMF1 gene expression
Mean relative SLAMF1 gene expression level measured by real-time quantitative polymerase chain reaction.
Measured: Baseline
Secondary outcomes (3)
BASDAI score
Mean Bath Ankylosing Spondylitis Disease Activity Index score (range 0 to 10, higher scores indicate higher disease activity).
Measured: Baseline
Erythrocyte sedimentation rate
Mean erythrocyte sedimentation rate in millimeters per hour.
Measured: Baseline
C-reactive protein
Mean C-reactive protein level in milligrams per liter.
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Oct 2026
- Study start30 Oct 2026 (estimated)
- Primary completion30 Oct 2027 (estimated)
- Study completion25 Mar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Ankylosing SpondylitisStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mennat-Allah Khaled Tolba Abdelraheem, Assiut University
- Investigators
- sohair K sayed, Study chair, Clinical pathology Department, Assiut University Hospitals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07907913
- Sponsor's protocol ID
- SLAMF1-AS-Assiut-2026
- Status last verified
- Oct 2026
- First submitted
- 26 Oct 2026
- Last updated
- 30 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of Signaling Lymphocytic Activation Molecule Family Member 1 (SLAMF1) Gene Expression in Patients With Ankylosing Spondylitis
- ClinicalTrials.gov ID
- NCT07907913
- Acronym / sponsor ID
- SLAMF1-AS-Assiut-2026
- Conditions
- Ankylosing Spondylitis
- Keywords
- SLAMF1, Gene expression, Ankylosing spondylitis, BASDAI, Assiut
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 30 Oct 2026 (estimated)
- Primary completion
- 30 Oct 2027 (estimated)
- Study completion
- 25 Mar 2028 (estimated)
- First posted
- 30 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This cross-sectional study aims to evaluate SLAMF1 gene expression levels in patients with ankylosing spondylitis compared with healthy controls.
Detailed description
Ankylosing spondylitis is a chronic immune-mediated inflammatory disease affecting the axial skeleton. SLAMF1 is a cell-surface immunoregulatory receptor expressed on immune cells that may play a role in inflammatory responses.
This observational study will measure relative SLAMF1 gene expression by real-time PCR in adult patients with ankylosing spondylitis and age- and sex-matched healthy controls.
Study design
- Observational model
- Case-control
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients with Ankylosing Spondylitis | – | –Adult patients diagnosed with ankylosing spondylitis. |
| Healthy Controls | – | –Age- and sex-matched apparently healthy adults without inflammatory rheumatic disease. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
- Study population
- Adult patients aged 18 years or older diagnosed with ankylosing spondylitis and age- and sex-matched healthy controls at Assiut University Hospitals.
Key inclusion criteria (4 listed)
- Adult Egyptian patients aged 18 years or older
- Diagnosed with ankylosing spondylitis according to established clinical criteria (patient group)
- Apparently healthy adults matched for age and sex (control group)
- Written informed consent
Key exclusion criteria (3 listed)
- Other concomitant systemic autoimmune or inflammatory rheumatic diseases
- Active acute infection at blood sampling
- Current malignancy or active anticancer treatment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
SLAMF1 gene expression
Time frame: Baseline
Mean relative SLAMF1 gene expression level measured by real-time quantitative polymerase chain reaction.
3 secondary outcomes
BASDAI score
Time frame: Baseline
Erythrocyte sedimentation rate
Time frame: Baseline
C-reactive protein
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Oct 2026.
- Individual participant dataSharing planned: No
Related trials for Ankylosing Spondylitis
Not yet recruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
RecruitingObservational study
Natural History and Development of Spondyloarthritis
Arthritis, Spondylitis, Ankylosing
Not yet recruitingPhase 1
Phase Ia Study of MST-931 in Healthy Adult Subjects
Ankylosing Spondylitis (AS)
Active, not recruitingObservational study
Frequency and Complications of Major Orthopedic Procedures in Medicare Beneficiaries
Rheumatoid Arthritis, Ankylosing Spondylitis
Not yet recruitingPhase 4
Ivarmacitinib With or Without Celecoxib for Ankylosing Spondylitis
Ankylosing Spondylitis (AS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
sohair K sayed study chair
Clinical pathology Department, Assiut University Hospitals
Questions about this trial
What is this clinical trial studying?
An observational study of Ankylosing Spondylitis, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 30 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mennat Allah K Tolba, Ass Lec (01093579968, mennatolba@aun.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
SLAMF1 gene expression (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Oct 2026.